ADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells $3,941,719.76 in Stock

ADMA Biologics, Inc. (NASDAQ:ADMA) Director Steve Elms sold 194,749 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director now directly owns 87,330 shares of the company’s stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Steve Elms also recently made the following trade(s):

• On Thursday, June 12th, Steve Elms sold 92,941 shares of ADMA Biologics stock. The stock was sold at an average price of $21.69, for a total transaction of $2,015,890.29.
• On Friday, June 13th, Steve Elms sold 137,931 shares of ADMA Biologics stock. The stock was sold at an average price of $20.82, for a total transaction of $2,871,723.42.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $20.40 on Tuesday. The stock’s 50-day moving average price is $20.99 and its two-hundred day moving average price is $18.83. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a market cap of $4.87 billion, a PE ratio of 72.86 and a beta of 0.47. ADMA Biologics, Inc. has a 1 year low of $10.21 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. ADMA Biologics’s quarterly revenue was up 40.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.08 EPS. On average, analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Institutional Trading of ADMA Biologics

Several institutional investors and hedge funds have recently bought and sold shares of ADMA. Nuveen LLC purchased a new position in ADMA Biologics during the 1st quarter valued at about $93,543,000. B Group Inc. purchased a new position in ADMA Biologics during the 4th quarter valued at about $39,231,000. Driehaus Capital Management LLC grew its stake in ADMA Biologics by 114.9% during the 1st quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company’s stock valued at $58,460,000 after acquiring an additional 1,575,363 shares in the last quarter. Invesco Ltd. grew its stake in ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company’s stock valued at $255,279,000 after acquiring an additional 1,570,649 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in ADMA Biologics during the 4th quarter valued at about $19,076,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. Wall Street Zen cut shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th. Finally, Raymond James boosted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.25.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.